ReviewTheranostics2021
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
Review in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration.Chemical science · 2026Article
- Adaptation of a Brain-Dedicated Multipinhole SPECT System for Imaging Higher-Energy Photons of Theranostic Agents-A Simulation Study.IEEE transactions on radiation and plasma medical sciences · 2026Article
- The Application of Radiolabeled Mesoporous Silica Nanoparticles in Molecular Imaging.Molecules (Basel, Switzerland) · 2026Review
- Potential therapeutic targeting of BKMolecular oncology · 2026Review
- Engineered exosomes for targeted glioma therapy: overcoming the blood-brain barrier with nature-inspired nanocarriers.Discover nano · 2026Review
- Decoding the Glioblastoma Microenvironment: AI-Driven Analysis of Cellular MRI Signatures for Targeted Therapy.Cellular and molecular neurobiology · 2026Review
- Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control.Frontiers in oncology · 2026Review
- Theranostic Potentials of Metallic Nanoparticles in Thyroid Diseases: Challenges and Prospects.International journal of nanomedicine · 2026Review
- Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges.Frontiers in pharmacology · 2026Review
- Review
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Locoregional radionuclide therapy of glioblastoma with [Scientific reports · 2025Article
- Precision radiotherapy with molecular-profiling of CNS tumours.Journal of neuro-oncology · 2025Review
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Pre-operative dual-time-point [European journal of nuclear medicine and molecular imaging · 2025Article
- Nanomedicine in Management of Cerebral Infarction and Brain Cancer: Role of Inflammation.Current medicinal chemistry · 2025Review
- Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.EJNMMI radiopharmacy and chemistry · 2024Article
- Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials.Targeted oncology · 2024Review
- Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?European journal of nuclear medicine and molecular imaging · 2024Review
- Clinical Theranostics in Recurrent Gliomas: A Review.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma (GB) remains a challenge. The current survival rate of GB averages one year, even with an optimal standard of care. However, the future promises efficient patient-tailored treatments, including targeted radionuclide therapy (TRT). Advances in radiopharmaceutical development have unlocked the possibility to assess disease at the molecular level allowing individual diagnosis. This leads to the possibility of choosing a tailored, targeted approach for therapeutic modalities. Therapeutic modalities based on radiopharmaceuticals are an exciting development with great potential to promote a personalised approach to medicine. However, an effective targeted radionuclide therapy (TRT) for the treatment of GB entails caveats and requisites. This review provides an overview of existing nuclear imaging and TRT strategies for GB. A critical discussion of the optimal characteristics for new GB targeting therapeutic radiopharmaceuticals and clinical indications are provided. Considerations for target selection are discussed, i.e. specific presence of the target, expression level and pharmacological access to the target, with particular attention to blood-brain barrier crossing. An overview of the most promising radionuclides is given along with a validation of the relevant radiopharmaceuticals and theranostic agents (based on small molecules, peptides and monoclonal antibodies). Moreover, toxicity issues and safety pharmacology aspects will be presented, both in general and for the brain in particular.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.